1.46
price up icon11.45%   0.15
pre-market  Pre-market:  1.46  
loading
Pepgen Inc stock is traded at $1.46, with a volume of 219.08K. It is up +11.45% in the last 24 hours and down -53.65% over the past month.
See More
Previous Close:
$1.31
Open:
$1.3
24h Volume:
219.08K
Relative Volume:
0.08
Market Cap:
$42.83M
Revenue:
-
Net Income/Loss:
$-87.23M
P/E Ratio:
-0.4916
EPS:
-2.97
Net Cash Flow:
$-82.77M
1W Performance:
-7.01%
1M Performance:
-53.65%
6M Performance:
-83.85%
1Y Performance:
-88.81%
1-Day Range:
Value
$1.30
$1.50
1-Week Range:
Value
$1.27
$1.64
52-Week Range:
Value
$1.16
$19.30

Pepgen Inc Stock (PEPG) Company Profile

Name
Name
Pepgen Inc
Name
Phone
703-456-8000
Name
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-08
Name
Latest SEC Filings
Name
PEPG's Discussions on Twitter

Compare PEPG with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PEPG
Pepgen Inc
1.46 42.83M 0 -87.23M -82.77M -2.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Pepgen Inc Stock (PEPG) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-16-24 Downgrade BofA Securities Neutral → Underperform
Jul-31-24 Downgrade BofA Securities Buy → Neutral
Dec-21-22 Initiated H.C. Wainwright Buy

Pepgen Inc Stock (PEPG) Latest News

pulisher
Apr 02, 2025

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace

Apr 02, 2025
pulisher
Apr 01, 2025

PepGen Announces Appointment of Two New Directors to its Board - BioSpace

Apr 01, 2025
pulisher
Mar 31, 2025

PepGen Inc. Expands Board with New Appointments - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

PepGen names two new directors to board - TipRanks

Mar 31, 2025
pulisher
Mar 28, 2025

PepGen CMO Mellion resigns, effective April 4 By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

PepGen CMO Mellion resigns, effective April 4 - Investing.com

Mar 28, 2025
pulisher
Mar 26, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen IncPEPG - Bluefield Daily Telegraph

Mar 26, 2025
pulisher
Mar 18, 2025

PEPG ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PepGen Inc. Shareholders Who Lost Money - ACCESS Newswire

Mar 18, 2025
pulisher
Mar 10, 2025

PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire

Mar 10, 2025
pulisher
Mar 10, 2025

PepGen Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsPEPG - ACCESS Newswire

Mar 10, 2025
pulisher
Mar 05, 2025

PepGen Inc. Faces Clinical Trial Challenges and Competitive Pressures Leading to Sell Rating - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

What Do Analysts Think Will Happen To PepGen Inc (NASDAQ: PEPG) - Stocks Register

Mar 05, 2025
pulisher
Mar 05, 2025

PepGen pauses Phase II DMD trial to review safety data - Clinical Trials Arena

Mar 05, 2025
pulisher
Mar 04, 2025

PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls - Benzinga

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Boston biotech's stock drops after Duchenne trial pause - The Business Journals

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen to pause CONNECT2-EDO51 study - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen slumps after pausing mid-stage study of Duchenne drug - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen pauses phase 2 DMD study to review earlier trial data - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD -March 04, 2025 at 08:18 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen stock slides after trial pause (PEPG:NASDAQ) - Seeking Alpha

Mar 04, 2025
pulisher
Mar 04, 2025

Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen to Participate in Upcoming Investor Conferences - Business Wire

Mar 04, 2025
pulisher
Mar 04, 2025

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable

Mar 04, 2025
pulisher
Mar 03, 2025

PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? - Asianet Newsable

Mar 03, 2025
pulisher
Mar 03, 2025

PepGen (PEPG) to Release Quarterly Earnings on Wednesday - Defense World

Mar 03, 2025
pulisher
Mar 01, 2025

Q1 Earnings Estimate for PepGen Issued By HC Wainwright - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Q1 Earnings Forecast for PepGen Issued By Leerink Partnrs - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

PepGen Inc. (NASDAQ:PEPG) Stock Analysis: Earnings Estimates, Analyst Ratings, and Market Performance - HPBL

Feb 28, 2025
pulisher
Feb 28, 2025

What is HC Wainwright’s Estimate for PepGen FY2025 Earnings? - Defense World

Feb 28, 2025
pulisher
Feb 28, 2025

PepGen (PEPG) Shares Rally In Extended Session - Stocks Telegraph

Feb 28, 2025
pulisher
Feb 28, 2025

Wedbush Weighs in on PepGen’s Q1 Earnings (NASDAQ:PEPG) - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

HC Wainwright Reiterates Buy Rating for PepGen (NASDAQ:PEPG) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Stock market news: Binah Capital Group +184.15%, PepGen +35.25% among top gainers during midday trading - Business Upturn

Feb 27, 2025
pulisher
Feb 27, 2025

Promising Prospects for PepGen Inc.: Buy Rating Affirmed Amid Positive DM1 Treatment Developments - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

What is HC Wainwright’s Estimate for PepGen Q1 Earnings? - Defense World

Feb 27, 2025
pulisher
Feb 26, 2025

PepGen CFO Noel Donnelly sells $2,565 in stock By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

PepGen general counsel DeLena sells $2,405 in stock - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

PepGen general counsel DeLena sells $2,405 in stock By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

PepGen CFO Noel Donnelly sells $2,565 in stock - Investing.com India

Feb 26, 2025
pulisher
Feb 26, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

PepGen reports positive initial data from Phase I DM1 therapy trial - MSN

Feb 26, 2025

Pepgen Inc Stock (PEPG) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):